Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pliant Therapeutics stock | $30.06

Learn how to easily invest in Pliant Therapeutics stock.

Pliant Therapeutics, Inc is a biotechnology business based in the US. Pliant Therapeutics shares (PLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pliant Therapeutics employs 90 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pliant Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PLRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pliant Therapeutics stock price (NASDAQ: PLRX)

Use our graph to track the performance of PLRX stocks over time.

Pliant Therapeutics shares at a glance

Information last updated 2021-07-28.
Latest market close$30.06
52-week range$19.43 - $43.92
50-day moving average $28.09
200-day moving average $31.23
Wall St. target price$51.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $0.27

Buy Pliant Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, ETFs
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Options, ETFs
$0 per year
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pliant Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pliant Therapeutics price performance over time

Historical closes compared with the close of $30.06 from 2021-05-28

1 week (2021-07-24) N/A
1 month (2021-07-02) 6.90%
3 months (2021-05-04) -13.99%
6 months (2021-01-31) N/A
1 year (2020-07-31) N/A
2 years (2019-07-31) N/A
3 years (2018-07-31) N/A
5 years (2016-07-31) N/A

Is Pliant Therapeutics under- or over-valued?

Valuing Pliant Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pliant Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pliant Therapeutics's EBITDA

Pliant Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.8 million.

The EBITDA is a measure of a Pliant Therapeutics's overall financial performance and is widely used to measure a its profitability.

Pliant Therapeutics financials

Revenue TTM $15.1 million
Gross profit TTM $41.8 million
Return on assets TTM -20.57%
Return on equity TTM -34.46%
Profit margin 0%
Book value $7.39
Market capitalisation $904.4 million

TTM: trailing 12 months

Shorting Pliant Therapeutics shares

There are currently 1.9 million Pliant Therapeutics shares held short by investors – that's known as Pliant Therapeutics's "short interest". This figure is 13.5% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting Pliant Therapeutics shares can be evaluated.

Pliant Therapeutics's "short interest ratio" (SIR)

Pliant Therapeutics's "short interest ratio" (SIR) is the quantity of Pliant Therapeutics shares currently shorted divided by the average quantity of Pliant Therapeutics shares traded daily (recently around 130851.27674258). Pliant Therapeutics's SIR currently stands at 14.49. In other words for every 100,000 Pliant Therapeutics shares traded daily on the market, roughly 14490 shares are currently held short.

However Pliant Therapeutics's short interest can also be evaluated against the total number of Pliant Therapeutics shares, or, against the total number of tradable Pliant Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pliant Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Pliant Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0998% of the tradable shares (for every 100,000 tradable Pliant Therapeutics shares, roughly 100 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Pliant Therapeutics.

Find out more about how you can short Pliant Therapeutics stock.

Pliant Therapeutics share dividends

We're not expecting Pliant Therapeutics to pay a dividend over the next 12 months.

Pliant Therapeutics overview

Pliant Therapeutics, Inc. , a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Frequently asked questions

What percentage of Pliant Therapeutics is owned by insiders or institutions?
Currently 9.473% of Pliant Therapeutics shares are held by insiders and 85.863% by institutions.
How many people work for Pliant Therapeutics?
Latest data suggests 90 work at Pliant Therapeutics.
When does the fiscal year end for Pliant Therapeutics?
Pliant Therapeutics's fiscal year ends in December.
Where is Pliant Therapeutics based?
Pliant Therapeutics's address is: 260 Littlefield Avenue, South San Francisco, CA, United States, 94080
What is Pliant Therapeutics's ISIN number?
Pliant Therapeutics's international securities identification number is: US7291391057
What is Pliant Therapeutics's CUSIP number?
Pliant Therapeutics's Committee on Uniform Securities Identification Procedures number is: 69912C105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site